



## Press Release

### Bliss GVS Pharma Limited (Bliss GVS)

October 26, 2020

#### Ratings

Instrument / Facility	Amount (Rs. crore)	Ratings	Rating Action
Long Term Bank Facilities – Term Loan	60.00	IVR BBB- / Stable (IVR Triple B Minus with Stable Outlook)	Assigned
Long Term Bank Facilities – Cash Credit	10.00	IVR BBB- / Stable (IVR Triple B Minus with Stable Outlook)	Assigned
Short Term Bank Facilities – Bill Discounting	40.00	IVR A3 (IVR A Three)	Assigned
Short Term Bank Facilities – Letter of Credit	15.00	IVR A3 (IVR A Three)	Assigned
<b>Total</b>	<b>125.00 (One Hundred and Twenty-Five)</b>		

Details of Facilities are in Annexure 1

#### Detailed Rationale

The ratings assigned to bank facilities of Bliss GVS Pharma Limited factors Long Operational Track Record; Experienced Management, Established market position and Robust financial risk profile. However, rating is constrained owing to working capital intensive nature of operations, Vulnerability to change in government/regulatory policies and volatility in raw material prices, Product and Geographical Concentration and Foreign Exchange fluctuation risk.

#### Key Rating Sensitivities:

##### Upward Factors

- Rating could be upgraded if there is sustainable reduction in working capital cycle to less than 250 days; Significant improvement in net cash accrual through improved scale of operations and improvement in profitability along with significant geographical diversification.



## Press Release

### **Downward Factors**

- Negative pressure on ratings could arise if any debt-funded capex/acquisitions/hive-off of profitable divisions lead to substantial deterioration in the company's credit profile;
- Further deterioration in debtors' profile could also impact ratings

### **List of Key Rating Drivers with Detailed Description**

#### **Key Rating Strengths**

##### **Long Operational Track Record; Experienced Management**

Bliss GVS has an operating record of over 35 years and the promoter, Mr S. N. Kamath, have more than three decades of experience in the pharmaceutical industry. This has enabled Company to establish strong relationships with various counterparties including suppliers and customers.

##### **Established market position**

Company has developed strong market position in the sub African region for its brands in the anti-malarial, dermatology and anti-inflammatory segments. Company is a leader in manufacturing suppositories and pessaries dosage forms. According to the management, Bliss GVS has market share of more than 75%, in private label sales of anti malarial segment in sub African region.

##### **Robust Financial Risk Profile**

The total operating income stood at Rs. 442 crores in FY2020 (Rs. 426.5 crores in FY2019) and EBITDA and PAT margins were at 22.66% & 19.36% respectively. The debt protection metrics is comfortable with Total Outside Liabilities to Tangible Network at 0.26x and overall gearing ratio at 0.14x. The Interest Service Coverage ratio is comfortable at 25.80x as of 31<sup>st</sup> March 2020.



## Press Release

### **Key Rating Weaknesses**

#### **Working capital intensive nature of operations**

Gross current assets were at 376 days as on March 31, 2020, on account of large export receivables. The company operates in multiple geographies and has a wide product portfolio; hence, it is required to maintain substantial inventory to ensure adequate supply. Further, the debtor days are expected to remain high on account of transit period of 90-100 days as well as credit period in the range of 3-4 months offered to the customers (primarily African countries).

#### **Vulnerability to change in government/regulatory policies and volatility in raw material prices**

The pharmaceutical industry is highly regulated, and hence, any adverse change in government/regulatory policies can impact the business risk profile of the Company. Having geographical presence in more than 64 emerging markets, Company needs to be constantly updated with the changing guidelines. Timely product and facility approval/renewal, in various semi-regulated markets, remains critical for the growth of exports going forward.

#### **Product and Geographical Concentration**

Around 85% of revenue comes from African countries, with concentration in revenue from top 3 customers being more than 50%, which significantly exposes the group's performance to geo political changes in the region. However, Company's new manufacturing facility at Vevoor, Maharashtra is expected to cater to other developed markets of USA and EU. This is expected to facilitate reduction of reliance on African region sales over FY22-FY24.

#### **Foreign Exchange fluctuation risk**

The company is exposed to currency fluctuation risk to the extent that there is a mismatch between the currencies in which Export sales, import purchase, other expenses and borrowings in foreign currency are denominated and the functional currency of the company. The currencies in which these transactions are primarily denominated are Euro and USD. The company uses forward exchange contracts to hedge its currency risk. Such contracts are generally designated as cash flow hedges. As on 31st March 2020, the company had



## Press Release

unhedged FCY exposure of INR 171.99 crores. In case of a 5% increase in the USD/INR currency the estimated total impact on the profit & loss would be about INR 8.5 crores. However, the company has adequate PAT to absorb losses arising due to the currency fluctuation.

**Analytical Approach:** Standalone

**Applicable Criteria:**

Rating Methodology for Manufacturing Companies

Financial Ratios & Interpretation (Non- Financial Sector)

### **Liquidity – Adequate**

Cash accruals are expected to be around Rs 100-130 crore per annum over the medium term which will be adequate to meet debt obligations and working capital requirement. Working Capital limits were utilised 62% on an average over the 12 months through September 2020. The group had reported cash and bank balance of Rs 86.62 crore as on March 31, 2020.

### **About the Company**

Bliss GVS Pharma Ltd, incorporated in 1984, is involved in manufacturing, marketing & exporting of more than 250 Branded Formulations that span across 20+ therapeutic segments and 16+ dosage forms. The company has a presence in more than 64 countries, with a major focus on the sub-Saharan African region. Its manufacturing facilities are located in Maharashtra which are certified as per ISO14001, OHSAS 18001, EU-GMP & WHO-GMP. Bliss also contract-manufactures suppositories and pessaries for domestic sales, for various domestic players. However, Bliss GVSS' revenue primarily consists of exports.

### **Financials (Standalone)\*:**

(In Crore)

For the year ended / As on	31-03-2018	31-03-2019	31-03-2020
	(Audited)	(Audited)	(Audited)
Total Operating Income	297.89	426.59	441.95
EBITDA	88.47	93.10	100.17



## Press Release

PAT	57.01	74.43	92.33
Total Debt	93.84	71.69	91.04
Adjusted Tangible Net-Worth	522.67	584.55	664.06
<b>Ratios</b>			
EBITDA Margin (%)	29.70	21.82	22.66
PAT Margin (%)	18.46	16.10	19.36
Overall Gearing Ratio (x)	0.17	0.12	0.13

\* Classification as per Infomerics' standards

**Status of non-cooperation with previous CRA:** None

**Any other information:** None

**Rating History for last three years:**

Sr. No.	Name of Instrument/Facilities	Current Ratings (Year 2020-21)			Rating History for the past 3 years		
		Type	Amount outstanding (Rs. Crore)	Rating	Date(s) & Rating(s) assigned in 2019-20	Date(s) & Rating(s) assigned in 2018-19	Date(s) & Rating(s) assigned in 2017-18
1.	Long Term Bank Facilities – Term Loan	Long Term	60.00	IVR BBB-/ Stable Outlook	--	--	--
2.	Long Term Bank Facilities – Cash Credit	Long Term	10.00	IVR BBB-/ Stable Outlook	--	--	--
3.	Short Term Bank Facilities – Bill Discounting	Short Term	40.00	IVR A3	--	--	--
4.	Short Term Bank Facilities – Letter of Credit	Short Term	15.00	IVR A3	--	--	--

**Note on complexity levels of the rated instrument:** Infomerics has classified instruments rated by it on the basis of complexity and a note thereon is available at [www.infomerics.com](http://www.infomerics.com).

**Name and Contact Details of the Rating Analyst:**

Name: Ruchi Shah Tel: (022) 62396023 Email: <a href="mailto:ruchi.shah@infomerics.com">ruchi.shah@infomerics.com</a>	Name: Prakash Kabra Tel: (022) 62396023 Email: <a href="mailto:Prakash.kabra@infomerics.com">Prakash.kabra@infomerics.com</a>
--	---



## Press Release

### About Infomerics:

Infomerics commenced rating & grading operations in April 2015 after having spent over 25 years in various segments of financial services. Infomerics is registered with the Securities and Exchange Board of India (SEBI) and accredited by Reserve Bank of India. It is gradually gaining prominence in domestic rating and/or grading space. Infomerics is striving for positioning itself as the most trusted & credible rating agency in the country and is gradually widening its product portfolio. Company's long experience in varied spectrum of financial services is helping it to fine-tune its product offerings to best suit the market.

**Disclaimer:** Infomerics ratings are based on information provided by the issuer on an 'as is where is' basis. Infomerics credit ratings are an opinion on the credit risk of the issue / issuer and not a recommendation to buy, hold or sell securities. Infomerics reserves the right to change, suspend or withdraw the credit ratings at any point in time. Infomerics ratings are opinions on financial statements based on information provided by the management and information obtained from sources believed by it to be accurate and reliable. The credit quality ratings are not recommendations to sanction, renew, disburse or recall the concerned bank facilities or to buy, sell or hold any security. We, however, do not guarantee the accuracy, adequacy or completeness of any information, which we accepted and presumed to be free from misstatement, whether due to error or fraud. We are not responsible for any errors or omissions or for the results obtained from the use of such information. Most entities whose bank facilities/instruments are rated by us have paid a credit rating fee, based on the amount and type of bank facilities/instruments. In case of partnership/proprietary concerns/Association of Persons (AOPs), the rating assigned by Infomerics is based on the capital deployed by the partners/proprietor/ AOPs and the financial strength of the firm at present. The rating may undergo change in case of withdrawal of capital or the unsecured loans brought in by the partners/proprietor/ AOPs in addition to the financial performance and other relevant factors.

### Annexure 1: Details of Facilities

Name of Facility	Size of Facility (Rs. Crore)	Maturity Date	Rating Assigned/ Outlook
Long Term Facility – Fund Based – Term Loan	60.00	June 2025	IVR BBB-/ Stable Outlook
Long Term Fund Based Facility – Cash Credit	10.00	N/A	IVR BBB-/ Stable Outlook
Short Term Fund Based – Bills Discounting	40.00	N/A	IVR A3
Short Term Non-Fund Based Facility – Letter of Credit	15.00	N/A	IVR A3